Clinical Trials

72 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05570253 2026-04-27

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

55 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07520760 2026-04-09

MBC-EA

52 enrolled

Breast Neoplasms

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

30 enrolled

Breast Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT05810870 2026-03-10

SABINA

14 enrolled

Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

26 enrolled

Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

83 enrolled

Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT07333937 2026-01-12

NETHER

35 enrolled

Brest Cancer

NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

13 enrolled 9 charts

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

37 enrolled

Inflammatory Breast Neoplasms

NCT07255612 2025-12-01

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

29 enrolled

Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

22 enrolled 12 charts

Inflammatory Breast Neoplasms

NCT05530057 2025-11-20

ESPERO

180 enrolled

Advanced Breast Cancer

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT01676818 2025-11-06

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

32 enrolled 17 charts

Gynecologic

Uterine Cervical Neoplasms

NCT07205185 2025-10-03

A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

46 enrolled

NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

57 enrolled 14 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

10 enrolled

HER2-negative Metastatic Breast Cancer

NCT02061085 2025-06-08

MERIBEL

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

NCT03222856 2025-06-05

KELLY

44 enrolled 17 charts

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

40 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

40 enrolled

Breast Neoplasms

NCT01827787 2024-11-06

Eribulin in HER2 Negative Metastatic BrCa

83 enrolled 18 charts

Breast Neoplasms

NCT03840772 2024-09-20

ERASING

16 enrolled

Sarcoma, Solitary Fibrous Tumors

NCT02681523 2024-09-19

ALERT

Phase 2 Terminated

8 enrolled 20 charts

Breast Neoplasms

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

60 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06387628 2024-08-02

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

74 enrolled

Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

54 enrolled

Triple Negative Breast Neoplasms

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

116 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

29 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT06308939 2024-03-13

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

81 enrolled

Breast Neoplasms

NCT03051659 2024-03-06

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

90 enrolled 13 charts

Breast Neoplasms

NCT06202313 2024-01-11

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

128 enrolled

Triple Negative Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

104 enrolled 16 charts

Breast Neoplasms, Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

123 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

56 enrolled 10 charts

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

52 enrolled 9 charts

Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

77 enrolled 9 charts

Breast Neoplasms

NCT05833919 2023-04-27

Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

80 enrolled

Breast Neoplasms

NCT03441360 2022-10-05

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

23 enrolled 14 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

40 enrolled

Triple Negative Breast Neoplasms

NCT03810976 2022-06-16

A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma

37 enrolled